What is the recommended diagnostic workup and management plan for a patient with progressive supranuclear palsy?

Progressive Supranuclear Palsy: Diagnostic Workup and Management

For a patient with suspected PSP, obtain brain MRI to look for midbrain atrophy (hummingbird sign) and consider ioflupane SPECT/CT to differentiate from essential tremor, while applying the 2017 Movement Disorder Society PSP criteria for clinical diagnosis. 1

Diagnostic Workup Algorithm

Clinical Recognition

PSP typically presents in the sixth or seventh decade (mean age 63) with specific features that distinguish it from idiopathic Parkinson's disease 1:

Key presenting features to identify:

• Lurching gait with unexplained falls (often the initial presentation)
• Axial dystonia and rigidity (more prominent than limb rigidity)
• Ocular symptoms: blurred vision, slow saccades early; vertical supranuclear gaze palsy appears later in disease course
• Poor or absent response to levodopa therapy 2
• Square wave jerks and eyelid opening apraxia 2

Apply the 2017 MDS-PSP criteria which identify 14 core clinical features and 4 clinical clues that combine to diagnose one of eight PSP phenotypes with probable, possible, or suggestive certainty 3. The most common phenotype is PSP-Richardson syndrome (PSP-RS), but recognize that PSP-parkinsonism (PSP-P), PSP-progressive gait freezing (PSP-PGF), and PSP-corticobasal syndrome (PSP-CBS) exist with different prognoses 4.

Imaging Strategy

MRI Brain (first-line imaging):

• Look for marked midbrain atrophy with preserved pontine volume creating the "hummingbird sign" (sagittal view) and "Mickey Mouse sign" (axial view) 2
• MRI is superior to CT for soft-tissue characterization and demonstrating regional volume loss patterns 1
• CT can demonstrate atrophy patterns but is not preferred 1

Ioflupane SPECT/CT (I-123 DaTscan):

• Valuable for differentiating Parkinsonian syndromes (PD, MSA, PSP, CBD) from essential tremor and drug-induced tremor 1
• Shows abnormality early in disease course compared to anatomic imaging
• In PSP, demonstrates bilateral putaminal dopaminergic deficit 2

FDG-PET/CT Brain (optional, limited evidence):

• Can discriminate PSP from idiopathic PD based on metabolic patterns 1
• PSP shows hypometabolism in medial frontal and anterior cingulate cortices, striatum, and midbrain 1
• Despite widespread use, very limited good-quality evidence supports routine use 1

Orthoptic oculomotor assessment:

• Highly effective for ruling PSP in or out, with 80.77% consistency with final neurological diagnosis 5
• Assess saccadic velocity, vergence, eyelid signs, and fixation 5

Differential Diagnosis Exclusion

Rule out PSP mimics including other tauopathies, corticobasal degeneration, multiple system atrophy, neurodegenerative disorders, genetic conditions, autoimmune and infectious disorders 6.

Management Plan

Pharmacological Approach

Levodopa trial is warranted but expect poor response 2. PSP characteristically shows minimal to no benefit from dopaminergic therapy, which helps distinguish it from idiopathic Parkinson's disease. No disease-modifying agents have shown benefit in recent trials 3.

Multidisciplinary Symptomatic Management

Early involvement of allied health professionals is critical 7, 8:

• Physical therapy: Address postural instability and fall risk
• Speech therapy: Manage dysphagia and hypophonia 2
• Occupational therapy: Adapt to functional decline
• Nutritional support: Address weight loss and swallowing difficulties 2

Patient-Centered Care Priorities

Focus on ameliorating symptoms, reducing fall risk and harm, and guiding patients through medical, social, and legal planning 8. Treatment should be proactive rather than reactive, considering both patient and family needs 8.

Prognostic Considerations

PSP-RS shows rapid progression with shorter survival (5-7 years), whereas PSP-P has a milder course (8-12 years) 4. Mean disease duration is approximately 6 years from onset 1. Early recognition enables appropriate supportive care planning and potential enrollment in clinical trials of tau-based therapeutics 3.

Common Pitfalls

• Waiting for vertical gaze palsy: This classic finding appears late in disease; don't delay diagnosis if other features are present 1
• Expecting levodopa response: Poor response is characteristic and helps confirm diagnosis 2
• Relying on clinical criteria alone: Biomarkers and imaging are needed for early-stage identification 6
• Missing phenotypic variants: PSP presents with multiple phenotypes beyond classic Richardson syndrome 7, 4